Stock ONPH ONCOLOGY PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Oncology Pharma Inc. Stock

Equities

ONPH

US68235J2015

Pharmaceuticals

Delayed OTC Markets
Other stock markets
 01:37:20 2024-04-15 pm EDT 		5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Oncology Pharma Inc. -99.90% -99.50%
2021 NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc. CI
2021 Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy CI

Financials (USD)

Sales 2003 3.28M Sales 2004 1.18M Capitalization 38
Net income 2003 -1M Net income 2004 -1M EV / Sales 2003 -
Net cash position 2003 1.35M Net Debt 2004 17K EV / Sales 2004 -
P/E ratio 2003 *
-
P/E ratio 2004
-
Employees -
Yield 2003 *
-
Yield 2004
-
Free-Float 100%
More Fundamentals * Assessed data

Chart Oncology Pharma Inc.

Dynamic Chart

Latest news about Oncology Pharma Inc.

NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc. CI
Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy CI
Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies CI
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent CI
Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology CI
Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board CI
Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform CI
Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer CI
Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc. CI
Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19 CI
Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners CI
Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc. CI
Oncology Pharma, Inc. Appoints Dr. Vijay Mahant as the Chief Scientific Officer and Chief Operating Officer CI
Oncology Pharma Elects Stefan Gruenwald to Its Board of Directors CI
Oncology Pharma Inc. Appoints Stefan Gruenwald as an Advisor on its Advisory Board CI
More news

Press releases Oncology Pharma Inc.

Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System PU
Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System PU
Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022 PU
Oncology Pharma : Financial Statements for the period ended December 31, 2021 PU
Oncology Pharma : Disclosure Statement for the period ended December 31, 2021 PU
More press releases

Highs and lows

1 week
0.00
Extreme 0
0.01
1 month
0.00
Extreme 0
0.18
Current year
0.00
Extreme 0
0.18
1 year
0.00
Extreme 0
1.05
3 years
0.00
Extreme 0
42.78
5 years
0.00
Extreme 0
50.00
10 years
0.00
Extreme 0
39 000.00
More quotes

Managers and Directors - Oncology Pharma Inc.

Managers TitleAgeSince
George Malesek CEO
 Chief Executive Officer - -
James B. Smith DFI
 Director of Finance/CFO - 21-01-27
Charles Wagner CHM
 Chairman - 14-09-29
Members of the board TitleAgeSince
Stefan Gruenwald BRD
 Director/Board Member - 19-10-07
Charles Wagner CHM
 Chairman - 14-09-29
Carlos Barnett BRD
 Director/Board Member - -
More insiders

Quotes

Date Price Change Volume
24-04-15 0.000001 0.00% 333
24-04-12 0.000001 -99.00% 24,684
24-04-11 0.0001 +9,900.00% 690
24-04-10 0.000001 -99.00% 1,200
24-04-09 0.0001 -90.00% 13,196

Delayed Quote OTC Markets, April 15, 2024 at 01:37 pm EDT

More quotes

Company Profile

Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company's research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company's NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.
Sector
Pharmaceuticals
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ONCOLOGY PHARMA INC. Stock Oncology Pharma Inc.
-99.50% 38
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.75% 676B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.27% 559B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 320B
ABBVIE INC. Stock AbbVie Inc.
+5.10% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.62% 213B
NOVARTIS AG Stock Novartis AG
+0.15% 207B
ROCHE HOLDING AG Stock Roche Holding AG
-9.41% 199B
AMGEN INC. Stock Amgen Inc.
-7.95% 142B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ONPH Stock